Macular Degeneration: all 1,490 studies
Page 4 of 15. Open to participants first (208), then studies with results posted, then the rest; newest registration first within each.
- Visual Activity Evoked by Infrared in Humans After Dark AdaptationCompletedNCT02909985Not applicableResults posted
- An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular DegenerationCompletedNCT02848313Phase 1Results posted
- Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMDCompletedNCT02800356Not applicableResults posted
- Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)TerminatedNCT02745119Phase 3Results posted
- Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMDCompletedNCT02732899Phase 2Results posted
- Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal InjectionCompletedNCT02713204Phase 2Results posted
- A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)CompletedNCT02698566Phase 3Results posted
- EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept InjectionCompletedNCT02689518Phase 4Results posted
- Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationCompletedNCT02686658Phase 2/3Results posted
- Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMDCompletedNCT02684578Phase 2Results posted
- A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic AtrophyCompletedNCT02659098Phase 2Results posted
- Alpha Lipoic Acid in Geographic AtrophyCompletedNCT02613572Phase 1/2Results posted
- Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular DegenerationCompletedNCT02611778Phase 3Results posted
- Role of Intravitreal Aflibercept Injection for the Treatment of Radiation MaculopathyCompletedNCT02586727Phase 2Results posted
- Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the EyeCompletedNCT02581891Phase 4Results posted
- Head to Head Study of Anti-VEGF Treatment.CompletedNCT02577107Phase 4Results posted
- Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.CompletedNCT02571972Phase 2Results posted
- Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular DegenerationCompletedNCT02569892Not applicableResults posted
- Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular DegenerationCompletedNCT02564978Phase 2Results posted
- A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular DegenerationCompletedNCT02555306Phase 1/2Results posted
- Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT02540954Phase 3Results posted
- SD-OCT AngiographyTerminatedNCT02510885Not applicableResults posted
- Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular DegenerationCompletedNCT02510794Phase 2Results posted
- Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular DegenerationCompletedNCT02507388Phase 2Results posted
- A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT02484690Phase 2Results posted
- A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular DegenerationCompletedNCT02462928Phase 3Results posted
- IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMDCompletedNCT02462889Phase 2Results posted
- Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular DegenerationCompletedNCT02462486Phase 3Results posted
- Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMDCompletedNCT02461771Phase 1Results posted
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 2CompletedNCT02434328Phase 3Results posted
- Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)TerminatedNCT02418754Phase 2Results posted
- Philadelphia Telemedicine Glaucoma Detection and Follow-Up StudyCompletedNCT02390245Not applicableResults posted
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedNCT02387957Phase 2Results posted
- Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT02358889Phase 2Results posted
- Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMDCompletedNCT02357342Phase 2Results posted
- LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular DegenerationCompletedNCT02355028Phase 2Results posted
- X-82 to Treat Age-related Macular DegenerationTerminatedNCT02348359Phase 2Results posted
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1CompletedNCT02307682Phase 3Results posted
- Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular DegenerationCompletedNCT02305238Phase 4Results posted
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular DegenerationActive, not recruitingNCT02286089Phase 1/2Results posted
- Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular DegenerationCompletedNCT02257632Phase 4Results posted
- Efficacy of Acupuncture in Macular DiseasesCompletedNCT02255981Not applicableResults posted
- A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT02247531Phase 3Results posted
- A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT02247479Phase 3Results posted
- Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular DegenerationTerminatedNCT02222207Phase 2Results posted
- Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDTerminatedNCT02214628Phase 2Results posted
- A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular DegenerationCompletedNCT02181517Phase 2Results posted
- A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular DegenerationCompletedNCT02181504Phase 2Results posted
- Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMDCompletedNCT02161575Phase 4Results posted
- Aflibercept After Ranibizumab in Exudative Age-related Macular DegenerationCompletedNCT02157077Phase 3Results posted
- Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.CompletedNCT02140411Phase 4Results posted
- A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD PatientsCompletedNCT02130024Phase 4Results posted
- A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular DegenerationCompletedNCT02121522Phase 2Results posted
- Aflibercept in Polypoidal Choroidal VasculopathyCompletedNCT02120950Phase 4Results posted
- Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGFCompletedNCT02118831Phase 1/2Results posted
- A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular DegenerationTerminatedNCT02087085Phase 2Results posted
- First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular DegenerationCompletedNCT02076919Phase 1Results posted
- Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment PhaseTerminatedNCT02032173Phase 3Results posted
- UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)CompletedNCT01988662Phase 4Results posted
- Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected EyeCompletedNCT01986907Phase 4Results posted
- A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective StudiesCompletedNCT01977846Results posted
- Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)CompletedNCT01972789Phase 4Results posted
- Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMDCompletedNCT01958918Phase 4Results posted
- Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal VasculopathyCompletedNCT01950741Phase 4Results posted
- Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMDCompletedNCT01948830Phase 3Results posted
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01944839Phase 3Results posted
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01940900Phase 3Results posted
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyTerminatedNCT01940887Phase 3Results posted
- Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular DegenerationCompletedNCT01926977Phase 1/2Results posted
- Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration StudyCompletedNCT01914159Phase 2Results posted
- ESBA1008 Microvolume StudyCompletedNCT01849692Phase 2Results posted
- Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)CompletedNCT01846273Phase 4Results posted
- Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular DegenerationCompletedNCT01835015Phase 1Results posted
- Effects of Sildenafil on Choroidal Thickness in AMDTerminatedNCT01830790Phase 2Results posted
- Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMDCompletedNCT01819415Not applicableResults posted
- Indocyanine Angiographic Changes of Choroidal Neovascularization by RanibizumabCompletedNCT01810042Phase 4Results posted
- Efficacy and Safety Study of ESBA1008 Versus EYLEA®CompletedNCT01796964Phase 2Results posted
- Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)Active, not recruitingNCT01782352Not applicableResults posted
- Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular DegenerationCompletedNCT01780935Phase 3Results posted
- Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)CompletedNCT01775124Phase 4Results posted
- Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular DegenerationCompletedNCT01773954Not applicableResults posted
- Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg RanibizumabCompletedNCT01748292Phase 3Results posted
- Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)CompletedNCT01722045Phase 4Results posted
- Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLOCompletedNCT01692938Results posted
- Pilot Study of X-82 in Patients With Wet AMDCompletedNCT01674569Phase 1/2Results posted
- Anesthesia Preference for Intravitreal Injection: Topical or SubconjunctivalCompletedNCT01640171Not applicableResults posted
- Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to AfliberceptCompletedNCT01617148Phase 4Results posted
- A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)TerminatedNCT01603043Phase 2Results posted
- Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular DegenerationTerminatedNCT01577381Phase 2Results posted
- Extension Study to Gather Data on Effect of Macugen on the Corneal EndotheliumCompletedNCT01573572Phase 4Results posted
- Study for Recalcitrant Age Related Macular DegenerationCompletedNCT01543568Phase 4Results posted
- Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular DegenerationCompletedNCT01528605Not applicableResults posted
- Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)CompletedNCT01527500Phase 2Results posted
- Safety and Tolerability Study for Age-Related Macular DegenerationCompletedNCT01485588Phase 1/2Results posted
- VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)CompletedNCT01482910Phase 3Results posted
- Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal MelanomaTerminatedNCT01471054Phase 2Results posted
- Study EvAluating Genotypes While Using Lucentis 2CompletedNCT01464723Phase 4Results posted
- Sirolimus for Advanced Age-Related Macular DegenerationCompletedNCT01445548Phase 1/2Results posted
- Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMDCompletedNCT01414153Phase 2Results posted
- Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With RanibizumabTerminatedNCT01402544Phase 2/3Results posted